Beta Bionics, Inc. (BBNX)
NASDAQ:BBNX
Want to see BBNX full AI Analyst Report?
BBNX Stock Chart & Stats
$12.98
--
Market closed
$12.98
--
Day’s Range― - ―
52-Week Range$8.80 - $32.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)781.72K
Market Cap
$641.24M
Enterprise Value$516.79M
Total Cash (Recent Filing)$199.52M
Total Debt (Recent Filing)$6.91M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 04, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding44,561,695
10 Day Avg. Volume871,597
30 Day Avg. Volume781,716
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)4.29
Price to Sales (P/S)12.32
P/FCF Ratio-21.97
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue4.69
Enterprise Value/Gross Profit8.20
Enterprise Value/Ebitda-7.44
Forecast
1Y Price Target
$17.67Price Target Upside36.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.16
Revenue Forecast (FY)$133.64M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial TractionBeta Bionics has rapidly scaled sales, delivering 57% YoY Q1 net sales growth and meaningful recurring revenue via pharmacy. The trend to convert users from MDI (~70% of new starts) and growing installed base supports durable revenue expansion and broader market penetration over the medium term.
Improving Gross Margins From Scale And Pharmacy MixGross margin expansion to ~59.5% (Q1) and raised full‑year gross margin guidance reflect durable leverage from pharmacy‑reimbursed recurring revenue, higher iLet production and lower materials cost. Sustained pharmacy mix and manufacturing scale should continue to structurally improve unit economics.
Strong Balance Sheet And LiquidityWith about $240M in cash and investments and minimal debt (debt-to-equity ~0.03 per balance sheet), Beta Bionics has financial flexibility to fund commercialization, R&D (Mint, bihormonal) and FDA remediation. This liquidity reduces short- to mid-term financing risk while scaling the business.
Bears Say
High Cash Burn & Negative Operating Cash FlowThe company is still consuming significant cash to grow: TTM operating cash flow and free cash flow are deeply negative, and Q1 cash burn (~$25M) remains material. Even with improving revenue, persistent negative cashflow creates reliance on existing liquidity and potential future financing until margins and scale fully offset spend.
Deep Ongoing Losses And Negative MarginsDespite revenue momentum, the business remains structurally unprofitable with TTM net and EBIT margins near -60%. High operating intensity (S&M ~75% of revenue) and continued R&D investment mean returns remain negative, delaying self-sufficiency and pressuring long-term profitability unless cost structure shifts.
FDA Warning Letter And Remediation RiskAn FDA warning letter requires remediation work that can consume management attention, extend timelines and increase compliance costs. Because Mint commercialization and broader product expansion depend on regulatory clearances, unresolved FDA items pose a durable operational and execution risk that could delay launches or limit market access.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.80 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $641.24M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 54 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Apr 21, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.503 by $0.013.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.58.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 44,561,695 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.503. Following the earnings report the stock price went down -0.57%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.67 (36.11% Upside)
$17.67 (36.11% Upside)
Blogger Sentiment
Bullish
BBNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 310.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $527.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.80%
12-Months-Change
Fundamentals
Return on Equity
-23.00%
Trailing 12-Months
Asset Growth
-9.94%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial momentum: strong 57% YoY revenue growth, meaningful gross margin expansion (59.5% in Q1), accelerating pharmacy channel adoption, raised full-year guidance and clear pipeline progress (Mint timing reiterated and Phase IIa for bihormonal started). Offsetting risks include a seasonal sequential decline in new patient starts, materially higher operating expenses (S&M at ~75% of revenue), ongoing FDA warning letter remediation, one-time tailwinds to Q1 gross margin that may not repeat, and continued investment-driven cash burn (~$25M in Q1). On balance, the positive operating results, guidance raises, cash runway and product/pipeline execution outweigh the near-term challenges and investments.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$17.67
▲(36.11% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
2.91% Insiders
9.52% Mutual Funds
66.98% Other Institutional Investors
11.66% Public Companies and
Individual Investors